Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb590885 SCHEMBL131578 | 1.00 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL14754822 | 1.00 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL15667975 | 0.97 | BRAF (0.93) | BRAFRAF1 | |
| Sb590885 SCHEMBL12518520 | 0.97 | BRAF (0.93) | BRAFRAF1 | |
| Sb590885 SCHEMBL15442151 | 0.97 | BRAF (0.93) | BRAFRAF1 | |
| Sb590885 SCHEMBL29353074 | 0.97 | BRAF (0.93) | BRAFRAF1 | |
| SCHEMBL5406959 | 0.96 | BRAF (0.92) | BRAFRAF1 | |
| SCHEMBL5406954 | 0.96 | BRAF (0.92) | BRAFRAF1 | |
| SCHEMBL5470151 | 0.91 | BRAF (0.83) | BRAFRAF1 | |
| SCHEMBL15449798 | 0.91 | BRAF (0.82) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013165320-A1 | TREATING CANCER BY INCREASING EXPRESSION OF SOCS6 | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-11-07 | — | — | WO | claimed |
| US-20120258461-A1 | METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT | THE UNITED STATES OF AMERICA AS REPRESENTED BY | 2012-10-11 | — | — | US | claimed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | claimed |
| EP-1318992-B1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2005-07-27 | — | — | EP | claimed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| US-12486539-B2 | Discriminating BRAF mutations | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4541379-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | SMITHKLINE BEECHAM CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-1492568-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTRATION OF AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SmithKline Beecham Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | BRAF, KRAS, NRAS | BRAF 1/4885RAF1 5/4885 |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | BRAF 3471/4885RAF1 3347/4885 |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885 |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.